Constitutive Connective Tissue Growth Factor Expression in Scleroderma Fibroblasts Is Dependent on Sp1
Open accessThe DOI matches its Crossref record.
Abstract
Fibrotic diseases such as scleroderma (systemic sclerosis, SSc) are characterized by an excessive production of extracellular matrix and profibrotic proteins such as connective tissue growth factor (CTGF). In normal dermal fibroblasts, CTGF is not expressed unless induced by proteins such as tumor growth factor-beta (TGFbeta). Conversely, in fibroblasts cultured from fibrotic lesions CTGF mRNA and protein are constitutively expressed, even in the absence of exogenously added TGFbeta. Thus, studying the mechanism underlying CTGF overexpression in SSc fibroblasts is likely to yield valuable insights into the basis of the fibrotic phenotype of SSc and possibly other scarring disease. CTGF overexpression is mediated primarily by sequences in the CTGF promoter. In this report, we identify the minimal promoter element involved with the overexpression of CTGF in SSc fibroblasts. This element is distinct from the element necessary and sufficient for the induction of CTGF expression by TGFbeta in normal fibroblasts. Within this region is a functional Sp1 binding site. Blocking Sp1 activity reduces the elevated, constitutive levels of CTGF promoter activity and protein expression observed in SSc fibroblasts. Relative to those prepared from normal dermal fibroblasts, nuclear extracts prepared from SSc fibroblasts possess increased Sp1 binding activity. Removal of phosphate groups from nuclear extracts enhanced Sp1 binding activity, suggesting that phosphorylation of Sp1 normally reduces Sp1 binding to DNA. Thus, the constitutive overexpression of CTGF in SSc fibroblasts seems to be independent of TGFbeta signaling but dependent at least in part on Sp1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
“However, models examining stages of established fibrosis do not show such activation, which suggests that overexpression of profibrotic markers is Smad independent (65, 92, 93).”
BackgroundSelf-citationAll in the CCN family: essential matricellular signaling modulators emerge from the bunker
Leask, A., & Abraham, D. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.03270 · Cited by 655
Self-citationFibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
Sakai, & Tager, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.001 · Cited by 285
Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases
Gressner, O. A., & Gressner, A. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01826.x · Cited by 270
Leask, A., & Abraham, D. J. (2003) · Biochemistry and Cell Biology · doi:10.1139/o03-069 · Cited by 261
Self-citationAlterations in the TGFβ signaling pathway in myogenic progenitors with age
Beggs, M. L., Nagarajan, R., Taylor‐Jones, J. M., Nolen, G., MacNicol, M., & Peterson, C. A. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00135.x · Cited by 74
Levinson, H. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0389 · Cited by 30
“CTGF has been widely studied for its effects on scarring.(65,69,70) Schultz and colleagues led a series of investigations to understand how antisense technology could be used to inhibit CTGF production and reduce scarring.”
Background
Metadata
- Authors
- Holmes, A., Abraham, D. J., Chen, Y., Denton, C., Shi-wen, X., Black, C. M., & Leask, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 43
- Pages
- 41728-41733
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2071349049
- Cited by
- 115
- References
- 0
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.